19th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160128964 | GEL COMPOSITIONS - Aqueous topical liposome gel compositions comprising ingenol-3-angelate. | 2016-05-12 |
20160128965 | GEL COMPOSITIONS - Novel aqueous topical gel compositions comprising ingenol-3-angelate. | 2016-05-12 |
20160128966 | METHODS FOR TREATING LEUKOPENIA AND THROMBOCYTOPENIA - The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor. | 2016-05-12 |
20160128967 | PROCESS AND COMPOSITION FOR STABILIZATION OF VULNERABLE PLAQUE UTILIZING A COMBINATION OF A STATIN AND OMEGA 3 FATTY ACIDS - A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition, the compositions and method designed to stabilize vulnerable plaque while mediating omega-3 deficiencies in individuals in need thereof. | 2016-05-12 |
20160128968 | METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) - This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound. | 2016-05-12 |
20160128969 | SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS - The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same. | 2016-05-12 |
20160128970 | COMPOSITION AND METHOD FOR TREATING NOSEBLEEDS - A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally. | 2016-05-12 |
20160128971 | Nanoparticle Compositions - The present invention relates to compositions and methods of formulating nanoparticle drugs for cancer treatment in particular for intravenous administration in particular nanoparticle formulations containing cytotoxic drugs for the treatment of cancer. The compositions may have properties which facilitate the release of drugs into the patient including being unstable in plasma/blood, having low AUC, low C | 2016-05-12 |
20160128972 | METHOD FOR PREVENTING INFLUENZA VIRUS INFECTION BY ADMINISTERING A DRY POWDER PHARMACEUTICAL COMPOSITION - A method for preventing an influenza virus infection by administering by inhalation to a patient a pharmaceutically effective amount of a dry powder composition containing | 2016-05-12 |
20160128973 | INHIBITION OF CANCER CELL MOTILITY - Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, KBU2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.). | 2016-05-12 |
20160128974 | ANTI-CXCR4 AS A SENSITIZER TO CANCER THERAPEUTICS - Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy. | 2016-05-12 |
20160128975 | ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF LUNG CANCER - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 2016-05-12 |
20160128976 | ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF CANCERS - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 2016-05-12 |
20160128977 | STABILIZED STATIN FORMULATIONS - The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same. | 2016-05-12 |
20160128978 | PHARMACEUTICAL FOR IMPROVING DYSPHAGIA - A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition. | 2016-05-12 |
20160128979 | MODIFIED RELEASE FORMULATION - Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia. | 2016-05-12 |
20160128980 | METHODS OF TREATING CKD USING PREDICTORS OF FLUID RETENTION - The disclosure relates to methods of treating chronic kidney disease and diabetic nephropathy using predictors of fluid retention to minimize the risk of adverse events. The methods disclosed are particularly useful in treatments involving endothelin receptor antagonists, and more particularly, atrasentan and pharmaceutically acceptable salts thereof. | 2016-05-12 |
20160128981 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF - Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders. | 2016-05-12 |
20160128982 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE - Antimicrobial compositions include at least one antimicrobial azole compound, particularly imidazole, triazole or thiazole compounds, and at least one polymeric biguanide compound. The compositions are useful in treating or preventing microbial infections of the skin and epithelial lined body cavities, such as ears. | 2016-05-12 |
20160128983 | CYTOTOXIC SUBSTANCE FOR USE IN COMBINATION WITH RADIOTHERAPY IN CANCER TREATMENT - The present invention provides a substance comprising a preparation of at least one chemotherapeutic or cytotoxic substance for the use in treatment of a disease of a mammalian patient, especially in the treatment of cancer. The invention suggests a symbiotic or synergistic combination of radiotherapy and chemotherapeutic or cytotoxic drug delivery. | 2016-05-12 |
20160128984 | ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or II to a patient in need thereof: | 2016-05-12 |
20160128985 | Methods and Compositions for the Treatment of Body Weight Related Disorders - The present invention relates to methods for reducing body weight in an animal in need thereof via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently. Also provided are methods for increasing thermogenesis without reducing lean body mass during weight loss in an animal by administering of a therapeutically effective amount of the compounds described. | 2016-05-12 |
20160128986 | METHODS AND COMPOSITIONS RELATED TO THE USE OF LOW HLB SURFACTANTS IN THE PRODUCTION OF SYNTHETIC NANOCARRIERS COMPRISING A RAPALOG - Disclosed are compositions and methods related to synthetic nanocarriers comprising a hydrophobic carrier material, a rapalog, and a non-ionic surfactant with a hydrophilic-lipophilic balance (HLB) value less than or equal to 10. | 2016-05-12 |
20160128987 | METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS WITH RAPAMYCIN IN A STABLE, SUPER-SATURATED STATE - Disclosed are compositions and methods that provide synthetic nanocarriers that comprise hydrophobic polyester carrier material and rapamycin that is in a stable, super-saturated amount. In some embodiments, the synthetic nanocarriers are also initially sterile filterable. In other embodiments, the rapamycin is present in the synthetic nanocarrier compositions in an amount that is less than 50 weight % rapamycin/hydrophobic polyester carrier material in the composition. | 2016-05-12 |
20160128988 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING A MPS-1 KINASE INHIBITOR AND A MITOTIC INHIBITOR - The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer. | 2016-05-12 |
20160128989 | PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER - The invention relates to the use of compounds corresponding to formula (I), or a pharmaceutically acceptable salt thereof, for preparing a medicament for the treatment of bladder cancer. | 2016-05-12 |
20160128990 | METHODS OF USING RIFAXIMIN IN POSITION EMISSION TOMOGRAPHY (PET) SCANS - The present invention provides new methods and kits for the reduction, prevention or inhibition of substrate uptake by non-metastatic, metabolically active cells in a subject who will undergo a position emission tomography (PET) scan. | 2016-05-12 |
20160128991 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-05-12 |
20160128992 | Methods for limiting acute kidney injury - Method of limiting development of acute kidney injury (AKI) and treating AKI using pyridoxamine are described, together with methods for monitoring efficacy of pyridoxamine therapy. | 2016-05-12 |
20160128993 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER - According to the invention there is provided a compound of formula (I) wherein: A represents C(═N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(═N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CR | 2016-05-12 |
20160128994 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES - Compositions and methods are described herein for the treatment of cystic diseases using PPARγ modulators. In particular, compositions and methods are described herein for the treatment of cystic diseases using low doses of PPARγ modulators. | 2016-05-12 |
20160128995 | METHODS FOR TREATING HEARTBURN AND/OR PREVENTING GASTRIC BLEEDING OR HEMORRHAGE IN PATIENTS RECEIVING CLOPIDOGREL THERAPY - The present invention relates to methods of treating heartburn in a patient receiving clopidogrel therapy. In another aspect, the present invention relates to methods of preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy. | 2016-05-12 |
20160128996 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS - This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R | 2016-05-12 |
20160128997 | SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS - The disclosure is directed to sustained-release buprenorphine formulations that provide long-term, therapeutic levels of buprenorphine for the treatment of pain and the maintenance treatment of opioid use disorders, such as opioid dependence. | 2016-05-12 |
20160128998 | Compositions and Methods Comprising Bupropion or Related Compounds for Sustained Delivery of Dextromethorphan - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2016-05-12 |
20160128999 | MASITINIB FOR TREATING HEPATIC CANCER - A method for treating hepatic cancer in a subject in need thereof, which includes the administration to the subject a therapeutically effective amount of a tyrosine kinase inhibitor, in combination with a therapeutically effective amount of a chemotherapeutic agent. | 2016-05-12 |
20160129000 | METHOD OF TREATMENT FOR MENTAL DISORDERS - The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D | 2016-05-12 |
20160129001 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS - Method for treating AML and MM by administration of a compound of the formula (I) | 2016-05-12 |
20160129002 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS - The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of Aβ-related diseases. | 2016-05-12 |
20160129003 | Pharmaceutical Combinations - A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, and (b) an anaplastic lymphoma kinase inhibitor, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the treatment or prevention of proliferative diseases; to pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination. | 2016-05-12 |
20160129004 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE - The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders. | 2016-05-12 |
20160129005 | ADENINE DERIVATIVES HAVING IMMUNOMODULATING ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY - The compound 2-[1-(6-aminopurin-9-yl)-2-oxoethoxy]prop-2-enal of formula: | 2016-05-12 |
20160129006 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF - Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed. | 2016-05-12 |
20160129007 | Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV - The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy by administering to a subject 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide. | 2016-05-12 |
20160129008 | Solid Dosage Form of Olmesartan Medoxomil and Amlodipine - The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof. | 2016-05-12 |
20160129009 | HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. | 2016-05-12 |
20160129010 | Substituted Benzoazepines as Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease. | 2016-05-12 |
20160129011 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES - BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), | 2016-05-12 |
20160129012 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATION THROUGH INHIBITION OF NTRK1 - The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (NTRK1)-based therapeutic agent, and related compositions and methods. | 2016-05-12 |
20160129013 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES - Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs. | 2016-05-12 |
20160129014 | FULVESTRANT FORMULATIONS - The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject. | 2016-05-12 |
20160129015 | Reduction of Side Effects from Aromatase Inhibitors Used for Treating Breast Cancer - The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent. | 2016-05-12 |
20160129016 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2016-05-12 |
20160129017 | SHIP INHIBITION TO COMBAT OBESITY - The present invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol. | 2016-05-12 |
20160129018 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES - In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies. | 2016-05-12 |
20160129019 | COMPOSITIONS, METHODS, AND SYSTEMS RELATING TO CONTROLLED CRYSTALLIZATION AND/OR NUCLEATION OF MOLECULAR SPECIES - The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent). | 2016-05-12 |
20160129020 | METHOD FOR TREATING RECURRING SKIN AND MUCOUS MEMBRANE DISEASES CAUSED BY HSV-1 AND HSV-2 - The invention relates to medicine and specifically to methods for treating recurring forms of diseases related to the family of herpes viruses. A method for treating recurring diseases of the skin and mucous membranes caused by HSV-1 and HSV-2 involves applying a preparation to an affected area, said preparation including a base containing 0.5% or 1% of an active substance, namely a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula (I): where X is Na, K, NH | 2016-05-12 |
20160129022 | Hydrogen Sulphide Compounds - The application describes Hydrogen Sulphide (H | 2016-05-12 |
20160129023 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 2016-05-12 |
20160129024 | NON-DIGESTIBLE OLIGOSACCHARIDES FOR ORAL INDUCTION OF TOLERANCE AGAINST DIETARY PROTEINS - Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins. | 2016-05-12 |
20160129025 | ANTI-FATIGUE COMPOSITION AND USE THEREOF - Disclosed is a composition with a sustainable anti-fatigue function and which helps the body to restore the level of high-energy phosphate materials and increases energy, wherein the active ingredients thereof are ribose and caffeine. The composition comprises components with the following weight parts: 1-99.9 parts ribose and 0.1-99 parts coffee or 1-99.99 parts ribose and 0.01-99 parts caffeine. | 2016-05-12 |
20160129026 | ANTIFUNGAL AND ANTIPARASITIC POLYENE MACROLIDES - In certain aspects, the present disclosure provides for novel, water-soluble polyene macrolides and salts or solvates thereof and methods of making the water-soluble polyene macrolides. Also provided are compositions and methods for inhibiting, preventing, and/or treating fungal and parasitic diseases in a subject. | 2016-05-12 |
20160129027 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE - Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed. | 2016-05-12 |
20160129028 | PHARMACEUTICAL COMPOSITIONS - Described herein are pharmaceutical compositions comprising a LMWH preparation having at least one chain having a glycol split uronic acid residue (UG) in the preparation and uses thereof. | 2016-05-12 |
20160129029 | THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT WITH CAPSIANOSIDE-TYPE COMPOUNDS - The present invention discloses the use of certain compounds as therapeutic agents, and in particular as analgesics and anti-inflammatory agents. Such compounds include, for example, certain diterpene monoglycosides and diterpene diglycosides. The compounds of the present invention may be synthesized or isolated from the fruit of the genus | 2016-05-12 |
20160129030 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS - Embodiments disclosed herein provide compositions and methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, e.g., lymphangioleiomyomatosis (LAM), LAM/TSC or treating and/or management of tuberous sclerosis complex (TSC). Such methods and compositions comprise at least one compound selected from the group consisting of nateglinide, Z-L-Phe chloromethyl ketone, clemastine fumarate, supercinnamaldehyde, practolol, fluvastatin Na, sulindac, BIO, amorolfine, spectinomucin, sibutramine HCl, nelfinavir mesylate, moroxydine HCl, nicotine ditartrate, trequinsin, meglumine, tizanidine HCl, CGP-74514A hydrochloride, tioconazole, TOVOK™ (afatinib), or kasugamycin. | 2016-05-12 |
20160129031 | PYRAZOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides pyrazole derivatives, uses thereof for medical purposes and so on. More particularly, the present invention relates to pharmaceuticals useful for the prevention or treatment of constipation, which comprise as an active ingredient 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide, or a pharmaceutically acceptable salt thereof. The pharmaceuticals of the present invention exert an effect of increasing the frequency of bowel movement or the like, and are useful for the prevention or treatment of constipation. | 2016-05-12 |
20160129032 | Receptor-Type Kinase Modulators and Methods of Use - The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR. | 2016-05-12 |
20160129033 | COMBINATION OF RO5503781 AND CAPECITABINE FOR CANCER THERAPY - There are provided pharmaceutical products comprising a) a first component comprising the compound of formula (A); and b) a second component comprising capecitabine for the simultaneous or sequential treatment of cancer, kits comprising said product as well as methods for treating cancer patients by administering said product. | 2016-05-12 |
20160129034 | COMBINATION OF RO5503781, CAPECITABINE AND OXALIPLANTIN FOR CANCER THERAPY - The present application discloses pharmaceutical products comprising a) as a first component a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of the compound of formula (A) or a pharmaceutically acceptable salt, ester or prodrug of said compound; b) a second component comprising a pharmaceutical composition comprising a therapeutically effective amount of capecitabine; and c) a third component comprising a pharmaceutical composition comprising a therapeutically effective amount of oxaliplatin. The application also discloses methods for the treatment of cancer using said products, as well as kits containing said products. | 2016-05-12 |
20160129035 | COMBINED ANTI-ACID-FAST BACTERIAL AGENT, SCREENING METHOD FOR ANTI-ACID-FAST BACTERIAL AGENTS, AND ACTIVITY INHIBITOR OF WecA OR ORTHOLOG THEREOF - A drug combination against acid-fast | 2016-05-12 |
20160129036 | ADENOSINE ANALOGS AND THEIR USE - The invention provides adenosine analog compounds that act at P2Y receptors, e.g., the P2Y | 2016-05-12 |
20160129037 | Multi-functional Composition and Preparation Method and Application Thereof - A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor. The marine algae-derived material is one from the group consisting of natural algal saccharide, alginic acid and alginate or is a mixture of several of them. The enzyme inhibitor is an inhibitor to the enzyme decomposing the material derived from marine algae. | 2016-05-12 |
20160129038 | MATERIALS AND METHODS FOR PREVENTING AND TREATING MICROBE-MEDIATED EPITHELIAL DISORDERS - The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as | 2016-05-12 |
20160129039 | Process For The Preparation Of A Non-Corrosive Base Solution And Methods Of Using Same - The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production including, but not limited to, gout, Lesch-Nyhan syndrome, hemochromatosis, Alzheimer's, amyotropic lateral sclerosis, arthritis, atherosclerosis, cancer, cataracts, chronic obstructive pulmonary disease, diabetes, cellulitis, coronary artery disease, heart failure, hypertension, inflammatory bowel disease, macular degeneration, multiple sclerosis, Parkinson's, Reynaud's phenomenon, reperfusion injury, pancreatic impairment, skin infections, Hepatitis C, methicillin-resistant | 2016-05-12 |
20160129040 | CHLORITE FORMULATIONS, AND METHODS OF PREPARATION AND USE THEREOF - Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein. | 2016-05-12 |
20160129043 | COMPOSITION OF MESENCHYMAL STEM CELLS - This invention relates in general to a mesenchymal stem cell (MSC) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells. More particularly, this invention relates to the isolation and applications of the neural crest derived gingiva mesenchymal stem cells and/or mesoderm derived gingiva mesenchymal stem cells. This invention also relates to a composition comprising a neural crest derived gingiva mesenchymal stem cell and/or a mesoderm derived gingiva mesenchymal stem cell. This composition may be used for wound healing and/or in the treatment of inflammatory and/or autoimmune diseases. | 2016-05-12 |
20160129044 | USE OF MESOTHELIAL CELLS IN TISSUE BIOENGINEERING AND ARTIFICIAL TISSUES - Use of mesothelial cells and artificial tissues comprising mesothelial cells in regenerative medicine, wherein the mesothelial cells have been cultivated in a Mesothelial Retaining Phenotype Media (MRPM) containing a glucocorticoid, Culture media, pharmaceutical compositions and uses thereof. | 2016-05-12 |
20160129045 | COMPOSITION FOR WOUND-HEALING COMPRISING ADULT STEM CELLS AND ELASTIN-LIKE POLYPEPTIDES - Provided is a composition for wound-healing containing adult stem cells and elastin-like polypeptides, and more specifically, to a composition for wound-healing capable of effectively treating skin wounds by simultaneously administering elastin-like polypeptides along with adult stem cells thereby increasing the viability of the adult stem cells transplanted on the wounds and promoting angiogenesis. | 2016-05-12 |
20160129046 | METHOD AND COMPOSITION OF INDUCING HAIR FOLLICLE NEOGENESIS - The present invention provides a method of inducing hair follicle neogenesis in the skin of a subject in need by transplanting the mixture of the skin extract or the composition with epidermal cells or fibroblasts into the subject. The skin extract of the present invention is obtained by mincing and mixing a skin tissue with phosphate buffer solution, thawing the skin tissue after freeze. And the composition of the present invention includes at least lumican, galectin-1 and apolipoprotein A-I. | 2016-05-12 |
20160129047 | CONDITIONED MEDIUM FROM HUMAN ADULT LIVER STEM CELLS AND ITS USE IN THE TREATMENT OF LIVER DISORDERS - The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous property ties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver. | 2016-05-12 |
20160129048 | Placental Stem Cell Populations - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 2016-05-12 |
20160129049 | PURIFIED AMNIOTIC MEMBRANE COMPOSITIONS AND METHODS OF USE - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 2016-05-12 |
20160129050 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 2016-05-12 |
20160129051 | AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-ANGIOGENESIS TREATMENT - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 2016-05-12 |
20160129052 | USE OF PROPOLIS FOR COMBATING THE SIDE EFFECTS OF CHEMOTHERAPY - The use of a composition including at least one extract of propolis containing polyphenols, as a human oral nutritional supplement or as a medicament for preventing and/or limiting the side effects of chemotherapy. | 2016-05-12 |
20160129053 | METHODS OF ISOLATING MICROORGANISMS AND USES THEREOF - Provided herein are methods for preparing a microbiome sample for transplantation into a subject in need thereof. In particular, the methods and compositions relate to methods of repopulating the the microbiome of a subject in the treatment of gastrointestinal maladies e.g., diarrhea and/or constipation. | 2016-05-12 |
20160129054 | Process for the therapeutic management of Diarrhea predominant irritable bowel syndrome using Bacillus coagulans SBC-37-01, MTCC 5856 - The present invention discloses a process for the therapeutic management of diarrhea predominant irritable bowel syndrome in humans comprising the oral administration of | 2016-05-12 |
20160129055 | PROBIOTIC BIFIDOBACTERIUM LONGUM - Regarding Deposited Microbial Organisms [EXPERT SOLUTION] | 2016-05-12 |
20160129056 | NUTRACEUTICAL SUPPLEMENT WITH LACTOBACILLUS RHAMNOSUS - Compositions and uses thereof include an admixture of a probiotic and natural phytochemicals that can affect an individual's stem cells and the inflammatory process to reduce underlying symptoms of various health issues, including arthritis, aging, and physical or athletic injuries, thereby facilitating healing and repair of tissues. | 2016-05-12 |
20160129057 | LACTOBACILLUS BREVIS G-101 STRAIN AND USE THEREOF - The present invention relates to a novel | 2016-05-12 |
20160129058 | NUTRITIONAL SUPPLEMENT SYSTEM - A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12. | 2016-05-12 |
20160129059 | MICROORGANISM BIOMASS FOR PREVENTION AND REDUCTION OF THE ADVERSE EFFECTS OF MYCOTOXINS IN DIGESTIVE TRACT - The present invention relates to microorganism biomass and a feed or food composition which can be used in preventing or reducing the adverse effects of mycotoxins in animal or human digestive tract. The biomass comprises non-living microorganism biomass obtainable by cultivating microorganism strains on a cultivation medium comprising lignocellulosic material. | 2016-05-12 |
20160129060 | Composition for the treatment of neurobehavioral disorders - The invention relates to a composition for use in the treatment of neurobehavioral disorders, a Cannabis plant extract comprising Cannabinol preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from | 2016-05-12 |
20160129061 | Pharmaceutical Composition and Health Functional Food Containing Red Ginseng Concentrate Having Enhanced Compound K for Preventing and Treating Non-alcoholic Fatty Liver Disease - The present invention relates to a pharmaceutical composition and a health functional food composition for preventing and treating non-alcoholic fatty liver disease, which comprises red | 2016-05-12 |
20160129062 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION - A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and | 2016-05-12 |
20160129063 | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa - The invention relates to a composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa comprising cranberry concentrate, urea, L-arginine, a buffer ensuring a pH value of the composition of 3.0 to 4.0, water and, optionally, additional active and/or auxiliary substances. The present invention also relates to a two-compartment blister pack containing the composition and to a kit comprising the two-compartment blister pack and an applicator fitting to the outlet channel of the blister pack easy to apply the composition to the desired areas. | 2016-05-12 |
20160129064 | METHOD FOR TREATING METABOLIC SYNDROME AND DIABETES USING QUERCETIN AND BAUHINIA FORFICATA EXTRACT - This invention relates to a method of treating metabolic syndrome and diabetes using a composition containing quercetin, vitamin B | 2016-05-12 |
20160129065 | COMPOSITION FOR PREVENTING AND TREATING GASTROINTESTINAL DISEASES, CONTAINING ESSENTIAL OILS EXTRACTED FROM LITSEA JAPONICA FRUIT - The present invention relates to a composition for preventing and treating gastrointestinal diseases by using | 2016-05-12 |
20160129066 | ALL NATURAL TOPICAL PAIN RELIEF CREAM - The present invention provides an all-natural, topical pain relief cream, with no artificial ingredients using Bentonite U.S.P. and sterile water U.S.P. as the foundation. The cream contains as active ingredients, one or more of menthol (regular or maximum strength), and salicin (methyl salicylate), with camphor and capsaicin as optional active ingredients. The vehicle includes coconut oil and lecithin to help retain the more volatile ingredients in with cream. | 2016-05-12 |